Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01209286 |
|
Recruitment Status :
Completed
First Posted : September 27, 2010
Results First Posted : January 7, 2015
Last Update Posted : March 6, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| B-ALL | Biological: Blinatumomab | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 36 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | An Open Label, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) |
| Study Start Date : | October 2010 |
| Actual Primary Completion Date : | March 2012 |
| Actual Study Completion Date : | October 2016 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Blinatumomab 15 μg
Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.
|
Biological: Blinatumomab
Continuous intravenous infusion over four weeks per treatment cycle
Other Names:
|
|
Experimental: Blinatumomab 5/15 μg
Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, followed by 15 μg/m²/day starting from Week 2 of treatment.
|
Biological: Blinatumomab
Continuous intravenous infusion over four weeks per treatment cycle
Other Names:
|
|
Experimental: Blinatumomab 5/15/30 μg
Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, a dose of 15 μg/m²/day in the subsequent 7 days, followed by 30 μg/m²/day starting from Week 3 of treatment.
|
Biological: Blinatumomab
Continuous intravenous infusion over four weeks per treatment cycle
Other Names:
|
- Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment [ Time Frame: Within the first 2 cycles of treatment, 12 weeks ]
At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria:
Complete Response/Remission (CR):
- Less than or equal to 5% blasts in the bone marrow
- No evidence of circulating blasts or extramedullar disease
-
Full recovery of peripheral blood counts:
- Platelets > 100,000/μL
- Hemoglobin ≥ 11 g/dL
- Absolute neutrophil count (ANC) > 1,500/μL
Complete Remission with only Partial Hematological Recovery (CRh*):
- Less than or equal to 5% blasts in the bone marrow
- No evidence of circulating blasts or extramedullar disease
-
Partial recovery of peripheral blood counts:
- Platelets > 50,000/μL
- Hemoglobin ≥ 7 g/dL
- ANC > 500/μL.
- Percentage of Participants With a Best Response of Complete Remission Within 2 Cycles of Treatment [ Time Frame: Within the first 2 cycles of treatment, 12 weeks ]
At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Complete Response/Remission (CR) was defined by the following criteria:
- Less than or equal to 5% blasts in the bone marrow
- No evidence of circulating blasts or extramedullar disease
-
Full recovery of peripheral blood counts:
- Platelets > 100,000/μL
- Hemoglobin ≥ 11 g/dL
- Absolute neutrophil count (ANC) > 1,500/μL
- Percentage of Participants With a Best Response of Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment [ Time Frame: Within the first 2 cycles of treatment, 12 weeks ]
At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Complete remission with only partial hematological recovery (CRh*) was defined by the following criteria:
- Less than or equal to 5% blasts in the bone marrow
- No evidence of circulating blasts or extramedullar disease
-
Partial recovery of peripheral blood counts:
- Platelets > 50,000/μL
- Hemoglobin ≥ 7 g/dL
- ANC > 500/μL.
- Percentage of Participants With a Best Response of Partial Remission Within 2 Cycles of Treatment [ Time Frame: Within the first 2 cycles of treatment, 12 weeks ]
At the end of each infusion period, a bone marrow aspiration/biopsy was performed to evaluate the efficacy of blinatumomab. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Partial remission was defined by the following criteria:
• Bone marrow blasts ≤ 25%
- Percentage of Participants With a Minimal Residual Disease (MRD) Response During the Core Study [ Time Frame: During the core study treatment period (up to 30 weeks). ]A minimal residual disease (MRD) response is defined as MRD < 10^-4 blasts/nucleated cells based on polymerase chain reaction (PCR) evaluation of individual rearrangements of immunoglobulin or T cell receptor genes.
- Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) After Treatment With Blinatumomab [ Time Frame: Up to the data cut-off date of 15 October 2012; maximum follow up time was 459 days ]The percentage of participants who underwent immediate allogeneic HSCT (defined as those in remission who undergo HSCT without receiving any other treatments) after having discontinued or completed the core study.
- Time to Hematological Relapse [ Time Frame: Up to the data cut-off date of 15 October 2012; maximum follow up time was 459 days. ]
Time to hematological relapse was measured for participants who achieved a CR or CRh* during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to disease progression. Participants without a documented relapse (hematological or extramedullary) and who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Participants who died without having reported hematological relapse or without showing any clinical sign of disease progression were censored on their day of death.
Hematological Relapse was defined as:
- Proportion of blasts in bone marrow > 5%
- Extramedullary relapse.
Time to hematological relapse was analyzed by Kaplan-Meier methods.
- Relapse-free Survival [ Time Frame: Up to the data cut-off date of 15 October 2012; maximum follow up time was 459 days. ]Relapse-free survival was measured only for participants who achieved a CR or CRh* during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to any cause. Participants without a documented relapse (hematological or extramedullary) or who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Relapse-free survival was estimated using Kaplan-Meier methods.
- Overall Survival [ Time Frame: Up to the data cut-off date of 15 October 2012; maximum follow up time was 667 days. ]Overall survival was measured for all participants from the date of first infusion of blinatumomab until the date of death due to any cause. Participants who did not die were censored on the last documented visit date. Overall survival was estimated using Kaplan-Meier methods.
- Number of Participants With Treatment-emergent Adverse Events [ Time Frame: From the start of the first infusion to 30 days after the end of the last infusion in the core study or from the start of the first retreatment cycle infusion to 30 days after the end of the last retreatment cycle; median treatment duration was 55.7 days. ]
Adverse events were evaluated for severity according to the grading scale provided in the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 and according to the following:
Grade I (mild); Grade 2 (moderate); Grade 3 (severe - significantly limits the patient's ability to perform routine activities despite symptomatic therapy; Grade 4 (life-threatening); Grade 5 (death).
The investigator used medical judgment to determine if there was a causal relationship (ie, certain, probable, possible, unlikely, not related) between an adverse event and blinatumomab.
A serious adverse event is any untoward medical occurrence or effect, that at any dose:
resulted in death, was life-threatening, required or prolonged hospitalization, resulted in persistent or significant disability or incapacity, is a congenital anomaly or birth defect or is a medically important condition.
- Steady State Blinatumomab Concentration [ Time Frame: Samples were collected at predose and at 48 hours following start of infusion, when dose is escalated and on Days 8, 15, 22, and 29 of the first 2 cycles. ]
The steady state concentration of blinatumomab was summarized as the observed concentrations collected at least 10 hours after the intravenous infusion was started for cycle 1 and cycle 2, respectively. Actual doses administered were used in the analysis.
Concentrations below the limit of detection (3 pg/mL) were set to zero before data analysis and concentrations below the lower limit of quantitation (50 pg/mL) were excluded from analysis.
- Clearance of Blinatumomab [ Time Frame: Samples were collected at predose and at 48 hours following start of infusion, when dose is escalated and on Days 8, 15, 22, and 29 of the first 2 cycles. ]Clearance was calculated as R0/Css; where R0 is the infusion rate (μg/m^2/hr) and Css is the steady state concentration.
- Serum Cytokine Peak Levels [ Time Frame: Samples were collected prior to treatment start (baseline), and at 2, 6, 24, and 48 hours after drug infusion start, and at these same time points when dose is escalated in each treatment cycle. ]The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN-γ) using multiplex cytometric bead assays. The lower limit of quantification (LLOQ) is 125 pg/mL and the limit of detection (LOD) is 20 pg/mL.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with B-precursor ALL relapsed after at least induction and consolidation or having refractory disease
- More than 5% blasts in bone marrow
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Life expectancy of ≥ 12 weeks
Exclusion Criteria:
- History or presence of clinically relevant central nervous system (CNS) pathology
- Infiltration of cerebrospinal fluid (CSF) by ALL
- Autologous/allogeneic hematopoietic stem cell transplantation (HSCT) within six weeks/three months prior to start of blinatumomab treatment
- Active Graft-versus-Host Disease (GvHD)
- Patients with Philadelphia chromosome (Ph)+ ALL eligible for treatment with dasatinib or imatinib
- Cancer chemotherapy within two weeks prior to start of blinatumomab treatment
- Immunotherapy (e.g. rituximab) within four weeks prior to start of blinatumomab treatment
- Infection with human immunodeficiency virus (HIV) or hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive)
- Pregnant or nursing women
- Previous treatment with blinatumomab
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01209286
| Germany | |
| Frankfurt, Germany | |
| Freiburg, Germany | |
| Hannover, Germany | |
| Kiel, Germany | |
| Münster, Germany | |
| Regensburg, Germany | |
| Tübingen, Germany | |
| Ulm, Germany | |
| Würzburg, Germany | |
| Principal Investigator: | Max Topp, MD | University of Wuerzburg |
| Responsible Party: | Amgen Research (Munich) GmbH |
| ClinicalTrials.gov Identifier: | NCT01209286 |
| Other Study ID Numbers: |
MT103-206 |
| First Posted: | September 27, 2010 Key Record Dates |
| Results First Posted: | January 7, 2015 |
| Last Update Posted: | March 6, 2017 |
| Last Verified: | July 2016 |
|
Blinatumomab B-ALL adult ALL relapsed ALL refractory ALL Leukemia |
ALL Lymphatic diseases Lymphoproliferative disorders bispecific antibody anti-CD19 Immunotherapeutic treatment |
|
Blinatumomab Leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Lymphoid Neoplasms by Histologic Type Neoplasms |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Antineoplastic Agents |